Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUAN C GARZA

Allopathic & Osteopathic Physicians Family Medicine

NPI
1669449971
CMS profile
165973
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$462.87

34 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $432.88 33
Education $29.99 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUAN C GARZA

NPI 1669449971 · CMS profile ID 165973

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669449971?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUAN C GARZA, NPI 1669449971, CMS profile ID 165973. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669449971?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JUAN C GARZA, NPI 1669449971, CMS profile ID 165973. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669449971?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JUAN C GARZA, NPI 1669449971, CMS profile ID 165973, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1669449971?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

34 matching records · $462.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 34 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–34 of 34.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $9.0612/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766867 CMS
AstraZeneca Pharmaceuticals LP $13.0411/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736132441 CMS
Novo Nordisk Inc $15.3010/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744944913 CMS
Novo Nordisk Inc $19.4110/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744930581 CMS
Novo Nordisk Inc $14.2409/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744917249 CMS
Novo Nordisk Inc $1.9109/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744917251 CMS
Allergan, Inc. $21.6809/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766863 CMS
Allergan, Inc. $10.0909/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766865 CMS
AstraZeneca Pharmaceuticals LP $17.2909/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736173379 CMS
Novo Nordisk Inc $12.0409/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744898599 CMS
Novo Nordisk Inc $13.3408/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744847389 CMS
Allergan, Inc. $13.5008/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766861 CMS
PFIZER INC. $6.1708/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743758333 CMS
Teva Pharmaceuticals USA, Inc. $15.5507/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749457177 CMS
AstraZeneca Pharmaceuticals LP $14.6406/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735810801 CMS
AstraZeneca Pharmaceuticals LP $13.0806/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735815347 CMS
Merck Sharp & Dohme Corporation $13.1806/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747724193 CMS
Allergan, Inc. $29.9905/20/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766859 CMS
Novo Nordisk Inc $14.3005/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744716401 CMS
Novo Nordisk Inc $9.3704/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744671771 CMS
Allergan, Inc. $22.9304/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766857 CMS
Novo Nordisk Inc $15.9804/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744663611 CMS
Genentech USA, Inc. $15.2103/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743038515 CMS
PFIZER INC. $9.5702/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743681351 CMS
PFIZER INC. $6.6602/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743681205 CMS
Allergan, Inc. $2.4102/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766855 CMS
Amarin Pharma Inc. $14.2802/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739939509 CMS
Novo Nordisk Inc $9.8702/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744588075 CMS
PFIZER INC. $1.3902/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743681209 CMS
AstraZeneca Pharmaceuticals LP $13.9002/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735953161 CMS
Allergan, Inc. $12.6701/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766853 CMS
AstraZeneca Pharmaceuticals LP $39.2401/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736299499 CMS
PFIZER INC. $6.4501/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743659613 CMS
Novo Nordisk Inc $15.1301/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744577705 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $697.42 45
PY2020 $462.87 34
PY2021 $606.41 45
PY2022 $1,514.63 68
PY2023 $1,566.78 94
PY2024 $1,681.91 93
PY2025 $1,387.30 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $43,373.43 14
PY2024 Principal investigator $171,802.76 70
PY2023 Recipient $23,812.92 7
PY2023 Principal investigator $383,116.06 124
PY2022 Principal investigator $624,521.08 179
PY2021 Principal investigator $663,885.83 360
PY2020 Principal investigator $248,213.43 166
PY2019 Principal investigator $403,386.63 210

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

360 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,872.45 12/24/2021 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832557151
Principal investigator 1 Novo Nordisk AS $2,027.23 12/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 811593557
Principal investigator 1 Alnylam Pharmaceuticals Inc. $19,016.10 12/22/2021 Non-covered Recipient Entity
VIP Trials LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417767
Principal investigator 1 Novo Nordisk AS $1,318.58 12/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811617053
Principal investigator 1 Novo Nordisk AS $1,866.16 12/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729383
Principal investigator 1 ABBVIE INC. $2,126.90 12/09/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792486211
Principal investigator 1 Novo Nordisk AS $3,850.49 12/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811617043
Principal investigator 1 PFIZER INC. $1,872.45 11/25/2021 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832849747
Principal investigator 1 Novo Nordisk AS $2,795.38 11/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593700
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,187.00 11/23/2021 Non-covered Recipient Entity
VIP Trials LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417741
Principal investigator 1 PFIZER INC. $5,488.98 11/10/2021 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832827553
Principal investigator 1 ABBVIE INC. $901.45 11/09/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792481805
Principal investigator 1 Novo Nordisk AS $1,166.72 10/29/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822697
Principal investigator 1 Novo Nordisk AS $5,775.73 10/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746641
Principal investigator 1 PFIZER INC. $2,204.55 10/22/2021 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832780453
Principal investigator 1 Novo Nordisk AS $23.06 10/18/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 810856487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $23,975.10 10/15/2021 Non-covered Recipient Entity
VIP Trials LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417773
Principal investigator 1 ABBVIE INC. $5,457.45 10/07/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792478071
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723879
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723885
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723891
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723897
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723903
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723909
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723915
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723921
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811723926
Principal investigator 1 Novo Nordisk AS $4.99 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811724157
Principal investigator 1 Novo Nordisk AS $350.00 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811724163
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797741
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797743
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797745
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797747
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797749
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797751
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797753
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797755
Principal investigator 1 Novo Nordisk AS $14.95 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797757
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797759
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811797761
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884797
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884799
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884801
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884803
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884805
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884807
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884809
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884811
Principal investigator 1 Novo Nordisk AS $1.00 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884813
Principal investigator 1 Novo Nordisk AS $9.99 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884815
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884817
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884819
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884821
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884823
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811884825
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811904347
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811904349
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811904351
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811904353
Principal investigator 1 Novo Nordisk AS $4.99 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811904355
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811904357
Principal investigator 1 Novo Nordisk AS $2.85 10/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX6018-4758 No dispute reported 06/30/2026 811904359
Principal investigator 1 Novo Nordisk AS $2,027.23 09/29/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 810856497
Principal investigator 1 PFIZER INC. $1,987.20 09/28/2021 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832699391
Principal investigator 1 Novo Nordisk AS $6,159.67 09/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870793
Principal investigator 1 Novo Nordisk AS $1,900.00 09/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593691
Principal investigator 1 Novo Nordisk AS $300.00 09/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811596767
Principal investigator 1 Novo Nordisk AS $50.00 09/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729377
Principal investigator 1 Novo Nordisk AS $3,411.08 09/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729455
Principal investigator 1 ABBVIE INC. $2,904.15 09/08/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792474255
Principal investigator 1 PFIZER INC. $2,204.55 09/02/2021 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832698145
Principal investigator 1 Novo Nordisk AS $2,189.16 08/30/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822797
Principal investigator 1 Novo Nordisk AS $23.06 08/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746631
Principal investigator 1 Novo Nordisk AS $5.20 08/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433167
Principal investigator 1 Novo Nordisk AS $1,691.82 08/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870779
Principal investigator 1 Novo Nordisk AS $1,120.50 08/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 811406723
Principal investigator 1 Novo Nordisk AS $2.75 08/18/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433161
Principal investigator 1 Novo Nordisk AS $23.06 08/18/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616927
Principal investigator 1 Novo Nordisk AS $23.06 08/16/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810753661
Principal investigator 1 Novo Nordisk AS $9.99 08/16/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433151
Principal investigator 1 Novo Nordisk AS $23.06 08/11/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 810739837
Principal investigator 1 Novo Nordisk AS $5.20 08/06/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870687
Principal investigator 1 Novo Nordisk AS $23.06 08/06/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433141
Principal investigator 1 Novo Nordisk AS $23.06 08/03/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433131
Principal investigator 1 Novo Nordisk AS $5.20 08/03/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616917
Principal investigator 1 PFIZER INC. $8,363.13 07/31/2021 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832895805
Principal investigator 1 ABBVIE INC. $12,484.15 07/29/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792469411
Principal investigator 1 Novo Nordisk AS $46.12 07/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870673
Principal investigator 1 Novo Nordisk AS $237.50 07/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026421
Principal investigator 1 Novo Nordisk AS $9.99 07/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746591
Principal investigator 1 Novo Nordisk AS $23.06 07/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746601
Principal investigator 1 Novo Nordisk AS $3,021.10 07/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870765
Principal investigator 1 Novo Nordisk AS $23.06 07/20/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 810856467
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 07/19/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516457
Principal investigator 1 Gilead Sciences, Inc. $4,750.00 07/19/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516459
Principal investigator 1 Gilead Sciences, Inc. $200.00 07/14/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516455
Principal investigator 1 ABBVIE INC. $4,407.90 07/08/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792466877
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,500.00 07/08/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025801
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,000.00 07/08/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025851
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,500.00 07/08/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025865
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $20,984.30 07/08/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025955
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $4,500.00 07/08/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026015
Principal investigator 1 Novo Nordisk AS $3,352.63 06/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810747025
Principal investigator 1 Novo Nordisk AS $450.00 06/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 811593597
Principal investigator 1 Novo Nordisk AS $3,222.89 06/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811596775
Principal investigator 1 Novo Nordisk AS $69.18 06/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,250.00 06/23/2021 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417695
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 06/23/2021 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 06/23/2021 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 06/23/2021 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417701
Principal investigator 1 Gilead Sciences, Inc. $3,372.00 06/23/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516453
Principal investigator 1 Novo Nordisk AS $9.99 06/09/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433111
Principal investigator 1 Novo Nordisk AS $23.06 06/09/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616907
Principal investigator 1 Novo Nordisk AS $2,141.67 05/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822855
Principal investigator 1 ABBVIE INC. $11,600.95 05/27/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792460201
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746447
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746457
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746467
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746477
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746485
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746495
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746505
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746515
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746525
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746535
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746543
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746553
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746561
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746571
Principal investigator 1 Novo Nordisk AS $13.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746581
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746611
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746621
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746669
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746679
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746689
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746699
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746709
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746719
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746729
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746739
Principal investigator 1 Novo Nordisk AS $2,996.40 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810747015
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822595
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822605
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822615
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822625
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822632
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822641
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822651
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822661
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822671
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822677
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822687
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822705
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822717
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822723
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822733
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822743
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822753
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822763
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822773
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822779
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822789
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870243
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870255
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870269
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870283
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870297
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870305
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870319
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870581
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870595
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870608
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870621
Principal investigator 1 Novo Nordisk AS $59.97 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870631
Principal investigator 1 Novo Nordisk AS $13.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870645
Principal investigator 1 Novo Nordisk AS $90.00 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870659
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870723
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870737
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870751
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810871063
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810871077
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810871091
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026157
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026171
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026185
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026197
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026209
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026223
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026237
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026249
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026263
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026277
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026289
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026303
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026317
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026329
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026341
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026355
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026367
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026381
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026395
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026409
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811432965
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811432975
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811432985
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811432993
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433003
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433013
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433023
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433033
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433043
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433053
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433063
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433073
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433081
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433091
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433101
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433197
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433207
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433247
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433257
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433263
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433273
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433283
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433293
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811592369
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811592379
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811592387
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811592397
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811592407
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811592417
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811592425
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811592435
Principal investigator 1 Novo Nordisk AS $450.00 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 811593587
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593653
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593663
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593671
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593681
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593709
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593719
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593729
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593739
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593749
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593757
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593765
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593775
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593785
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593795
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593805
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593815
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811593825
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811596747
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811596757
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616723
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616733
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616743
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616752
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616761
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616773
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616781
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616789
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616799
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616809
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616819
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616829
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616839
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616849
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616859
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616869
Principal investigator 1 Novo Nordisk AS $7.65 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616879
Principal investigator 1 Novo Nordisk AS $9.75 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616887
Principal investigator 1 Novo Nordisk AS $54.00 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616897
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616955
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616963
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616973
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616983
Principal investigator 1 Novo Nordisk AS $16.25 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616993
Principal investigator 1 Novo Nordisk AS $28.45 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811617023
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811617033
Principal investigator 1 Novo Nordisk AS $24.95 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811645235
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729259
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729265
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729271
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729277
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729283
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729289
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729293
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729299
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729305
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729311
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729317
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729323
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729329
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729335
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729341
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729347
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729353
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729359
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729365
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729371
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729389
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729395
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729401
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729407
Principal investigator 1 Novo Nordisk AS $32.50 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729411
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729417
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729423
Principal investigator 1 Novo Nordisk AS $5.30 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729429
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729436
Principal investigator 1 Novo Nordisk AS $56.90 05/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729441
Principal investigator 1 Gilead Sciences, Inc. $49,992.00 05/19/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 05/13/2021 Non-covered Recipient Entity
VIP Trials LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417731
Principal investigator 1 ABBVIE INC. $1,828.60 04/29/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792448435
Principal investigator 1 Gilead Sciences, Inc. $65,028.00 04/26/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516449
Principal investigator 1 Novo Nordisk AS $5,299.83 04/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729461
Principal investigator 1 Novo Nordisk AS $2,020.50 04/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 810743485
Principal investigator 1 Novo Nordisk AS $12,073.47 04/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811619823
Principal investigator 1 Novo Nordisk AS $23.06 04/19/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 811406713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/15/2021 Non-covered Recipient Entity
VIP Trials LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 04/15/2021 Non-covered Recipient Entity
VIP Trials LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/15/2021 Non-covered Recipient Entity
VIP Trials LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $35.00 04/15/2021 Non-covered Recipient Entity
VIP Trials LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417729
Principal investigator 1 ABBVIE INC. $3,592.85 03/30/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792436619
Principal investigator 1 Novo Nordisk AS $7,551.48 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810753337
Principal investigator 1 Novo Nordisk AS $250.00 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822845
Principal investigator 1 Novo Nordisk AS $4,959.01 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811026433
Principal investigator 1 Novo Nordisk AS $9.99 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433227
Principal investigator 1 Novo Nordisk AS $23.06 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433237
Principal investigator 1 Novo Nordisk AS $250.00 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811619813
Principal investigator 1 Novo Nordisk AS $69.18 03/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746659
Principal investigator 1 Gilead Sciences, Inc. $105,084.00 03/17/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516447
Principal investigator 1 ABBVIE INC. $174.15 03/03/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792431425
Principal investigator 1 ABBVIE INC. $1,610.65 02/26/2021 Non-covered Recipient Entity
VIP TRIALS
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792425997
Principal investigator 1 Novo Nordisk AS $9.99 02/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810746649
Principal investigator 1 Novo Nordisk AS $250.00 02/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 811406701
Principal investigator 1 Novo Nordisk AS $23.06 02/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811617013
Principal investigator 1 PFIZER INC. $11,750.00 02/23/2021 Non-covered Recipient Entity
VIP Trials
A PHASE 2B RANDOMIZED DOUBLEBLIND PARALLELGROUP PLACEBOCONTROLLED STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF PF06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832751299
Principal investigator 1 Gilead Sciences, Inc. $635.93 02/22/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516445
Principal investigator 1 Novo Nordisk AS $1,546.76 02/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 810822839
Principal investigator 1 Gilead Sciences, Inc. $3,297.00 02/17/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516441
Principal investigator 1 Gilead Sciences, Inc. $119,514.00 02/17/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516443
Principal investigator 1 Novo Nordisk AS $5.20 02/16/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870805
Principal investigator 1 Novo Nordisk AS $23.06 02/16/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811617003
Principal investigator 1 Novo Nordisk AS $46.12 02/15/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616947
Principal investigator 1 Novo Nordisk AS $23.06 02/11/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4321 No dispute reported 06/30/2026 810739827
Principal investigator 1 Novo Nordisk AS $41.06 02/05/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433177
Principal investigator 1 Novo Nordisk AS $9.99 02/05/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811616937
Principal investigator 1 PFIZER INC. $5,768.43 02/05/2021 Non-covered Recipient Entity
VIP Trials LLC
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 832797431
Principal investigator 1 Novo Nordisk AS $246.36 02/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870699
Principal investigator 1 Novo Nordisk AS $41.06 02/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870711
Principal investigator 1 Novo Nordisk AS $9.99 02/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 811433187
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 02/03/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516433
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 02/03/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516435
Principal investigator 1 Gilead Sciences, Inc. $2,500.00 02/03/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516437
Principal investigator 1 Gilead Sciences, Inc. $3,000.00 02/03/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516439
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 02/01/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516427
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 02/01/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516429
Principal investigator 1 Gilead Sciences, Inc. $17,364.00 02/01/2021 Non-covered Recipient Entity
VIP TRIALS
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803516431
Principal investigator 1 Novo Nordisk AS $3,243.82 01/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4352 No dispute reported 06/30/2026 810870229
Principal investigator 1 Novo Nordisk AS $1,530.70 01/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
EX9536-4388 No dispute reported 06/30/2026 811729252